NOXXON Pharma AG Revenue and Competitors

Berlin, Germany

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • NOXXON Pharma AG's estimated annual revenue is currently $8M per year.(i)
  • NOXXON Pharma AG's estimated revenue per employee is $201,000

Employee Data

  • NOXXON Pharma AG has 40 Employees.(i)
  • NOXXON Pharma AG grew their employee count by 14% last year.

NOXXON Pharma AG's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$17.7M887%N/AN/A
#2
$89.4M4459%N/AN/A
#3
$32.4M16125%N/AN/A
#4
$44.4M2217%N/AN/A
#5
$120.2M42717%$446.2MN/A
#6
$54.3M27010%N/AN/A
#7
$49.6M24752%N/AN/A
#8
$21.9M109-1%N/AN/A
#9
$16.5M824%N/AN/A
#10
$26.7M13325%N/AN/A
Add Company

What Is NOXXON Pharma AG?

NOXXON Pharma is a clinical-stage biopharmaceutical company whose core focus is on improving cancer treatment by targeting the tumor microenvironment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON's pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.

keywords:N/A

N/A

Total Funding

40

Number of Employees

$8M

Revenue (est)

14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NOXXON Pharma AG News

2022-04-17 - Le marché de la leucémie lymphoïde chronique connaîtra une ...

Noxxon Pharma AG, MedImmune, LLC, Novartis AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Celgene Corporation,...

2022-04-13 - Global Rhabdomyosarcoma Drug Market 2022 Outlook and ...

Novartis AG; Noxxon Pharma AG; Pfizer Inc; Taiho Pharmaceutical Co Ltd; Taiwan Liposome Company Ltd; Tarveda Therapeutics Inc. On the global...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.8M40-11%N/A
#2
$4.5M400%N/A
#3
$8.6M4011%N/A
#4
$4.6M4014%N/A
#5
$4.5M40-9%N/A